Effectiveness of Ammonium Chloride in Reducing Viral Load
NCT ID: NCT07254052
Last Updated: 2025-11-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
32 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-09-01
Study Completion Date
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective, double-blind, randomized, comparative effectiveness pilot study evaluating the effect of a sustained-release ammonium chloride formulation (ACF) on viral load dynamics in adult patients with mild or moderate COVID-19 or seasonal influenza infection.
Eligible participants are randomly assigned in a 1:1 ratio to receive either ACF (ammonium chloride with vitamin D) or a control formulation (vitamin D only) twice daily for 10 consecutive days. The primary objective is to assess the reduction of viral load measured by RT-PCR cycle threshold (Ct) values at baseline, Day 3-5, and Day 10-12. Secondary objectives include the duration and severity of symptoms, incidence of hospitalization, oxygen supplementation, ICU admission, and mortality.
The study is conducted in both inpatient and outpatient settings at Sotiria General Hospital for Chest Diseases, Athens, Greece as well as at the outpatient clinic "En Ygeia". All viral load analyses are performed at the Department of Pharmacy, National and Kapodistrian University of Athens. A total of 32 participants were enrolled. This study aims to generate early clinical evidence regarding the antiviral effectiveness of ACF as an adjunct strategy in respiratory RNA virus infections.
Eligible participants are randomly assigned in a 1:1 ratio to receive either ACF (ammonium chloride with vitamin D) or a control formulation (vitamin D only) twice daily for 10 consecutive days. The primary objective is to assess the reduction of viral load measured by RT-PCR cycle threshold (Ct) values at baseline, Day 3-5, and Day 10-12. Secondary objectives include the duration and severity of symptoms, incidence of hospitalization, oxygen supplementation, ICU admission, and mortality.
The study is conducted in both inpatient and outpatient settings at Sotiria General Hospital for Chest Diseases, Athens, Greece as well as at the outpatient clinic "En Ygeia". All viral load analyses are performed at the Department of Pharmacy, National and Kapodistrian University of Athens. A total of 32 participants were enrolled. This study aims to generate early clinical evidence regarding the antiviral effectiveness of ACF as an adjunct strategy in respiratory RNA virus infections.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19
NCT05365321
COVID-19
Mechanical Ventilation Complication
COVID-19 Acute Respiratory Distress Syndrome
UNKNOWN
PHASE1/PHASE2
To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects
NCT06485401
Influenza Type A
Influenza Type B
COMPLETED
PHASE1
ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection
NCT06342921
Safety Issues
Effect of Drug
COMPLETED
PHASE2/PHASE3
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
NCT04375098
Severe Acute Respiratory Syndrome Coronavirus 2
COMPLETED
PHASE2
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
NCT04328285
COVID-19
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, double-blind, randomized, comparative effectiveness pilot clinical study designed to evaluate the antiviral effect of a sustained-release ammonium chloride formulation (ACF) in adult patients with mild or moderate SARS-CoV-2 or seasonal influenza infection. Respiratory viral infections remain a major global health burden, and safe, accessible adjunct therapies are needed to complement existing public health measures and vaccination strategies.
Eligible participants are adults (≥18 years) with a positive rapid test for SARS-CoV-2 or influenza A/B, recruited at the Outpatients Clinic or Emergency Department of Sotiria General Hospital for Chest Diseases and at "En Ygeia" outpatient clinic. Participants are randomized in a 1:1 ratio to receive either:
1. ACF (nutritional supplement): sustained-release ammonium chloride formulation with vitamin D, one capsule every 12 hours for 10 days
2. VDF (control): matched sustained-release placebo formulation containing only vitamin D, one capsule every 12 hours for 10 days.
Both inpatients and outpatients are included. Exclusion criteria are: age \<18 years, pregnancy or lactation, denial of informed consent, known allergy to study components, organ transplantation, and frailty score ≥5. Participants may discontinue the study in cases of intolerance, non-compliance, or withdrawal of consent.
The primary endpoint is the reduction of viral load, assessed through RT-PCR cycle threshold (Ct) values obtained at baseline (Day 1), Day 3-5, and Day 10-12.
Secondary endpoints include:
* Duration and severity of symptoms for 30 days
* Incidence of hospitalization (for outpatients)
* Need for oxygen supplementation
* ICU admission
* Intubation
* Death. All RT-PCR testing for SARS-CoV-2 and influenza A/B were performed at the Department of Pharmacy, National and Kapodistrian University of Athens. The study employs standardized sampling, nucleic acid extraction, and real-time PCR quantification with certified reference materials.
Statistical analysis compared Ct values across timepoints within and between groups. Mean percentage change in Ct values was compared using appropriate parametric or non-parametric tests, with additional analyses for secondary outcomes. The final sample size was 32 patients.
This pilot trial aims to provide early clinical evidence regarding the potential antiviral effectiveness of ammonium chloride in the context of mild respiratory viral infections, contributing to the design of larger confirmatory studies.
Eligible participants are adults (≥18 years) with a positive rapid test for SARS-CoV-2 or influenza A/B, recruited at the Outpatients Clinic or Emergency Department of Sotiria General Hospital for Chest Diseases and at "En Ygeia" outpatient clinic. Participants are randomized in a 1:1 ratio to receive either:
1. ACF (nutritional supplement): sustained-release ammonium chloride formulation with vitamin D, one capsule every 12 hours for 10 days
2. VDF (control): matched sustained-release placebo formulation containing only vitamin D, one capsule every 12 hours for 10 days.
Both inpatients and outpatients are included. Exclusion criteria are: age \<18 years, pregnancy or lactation, denial of informed consent, known allergy to study components, organ transplantation, and frailty score ≥5. Participants may discontinue the study in cases of intolerance, non-compliance, or withdrawal of consent.
The primary endpoint is the reduction of viral load, assessed through RT-PCR cycle threshold (Ct) values obtained at baseline (Day 1), Day 3-5, and Day 10-12.
Secondary endpoints include:
* Duration and severity of symptoms for 30 days
* Incidence of hospitalization (for outpatients)
* Need for oxygen supplementation
* ICU admission
* Intubation
* Death. All RT-PCR testing for SARS-CoV-2 and influenza A/B were performed at the Department of Pharmacy, National and Kapodistrian University of Athens. The study employs standardized sampling, nucleic acid extraction, and real-time PCR quantification with certified reference materials.
Statistical analysis compared Ct values across timepoints within and between groups. Mean percentage change in Ct values was compared using appropriate parametric or non-parametric tests, with additional analyses for secondary outcomes. The final sample size was 32 patients.
This pilot trial aims to provide early clinical evidence regarding the potential antiviral effectiveness of ammonium chloride in the context of mild respiratory viral infections, contributing to the design of larger confirmatory studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
RNA Virus Infections
Viral Infection COVID-19
Influenza A and B
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACF receiving participants
Participants assigned to this group received the sustained-release ammonium chloride formulation (ACF), containing 500 mg ammonium chloride and 2,000 IU vitamin D per capsule. One capsule was administered orally every 12 hours for 10 consecutive days, starting on Day 1. Both inpatients and outpatients with mild or moderate COVID-19 or seasonal influenza infection were included. The intervention aimed to evaluate the effect of ammonium chloride on viral load reduction and clinical outcomes compared to the control group. Randomization and double-blinding were maintained throughout the study.
No interventions assigned to this group
Control Group (VDF receiving participants)
Participants assigned to this group received the control formulation consisting of sustained-release tablets containing 2,000 IU vitamin D and identical excipients, but no ammonium chloride. One capsule was administered orally every 12 hours for 10 consecutive days, starting on Day 1. Both inpatients and outpatients with mild or moderate COVID-19 or seasonal influenza infection were included. This control arm was used to compare changes in viral load dynamics and clinical outcomes against the intervention group. Randomization and double-blinding were maintained throughout the study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults ≥ 18 years.
* Positive rapid test for Sars-CoV-2 19 or influenza (performed at the Outpatients Clinic or the Emergency Department).
* Informed consent.
* Positive rapid test for Sars-CoV-2 19 or influenza (performed at the Outpatients Clinic or the Emergency Department).
* Informed consent.
Exclusion Criteria
* Age \< 18 years.
* Pregnancy, and/or lactation.
* Denial of Informed Consent.
* Known allergy to ammonium chloride or to any of the ACF, or VDF excipients.
* Organ transplantation.
* Frailty score ≥ 5.
* Pregnancy, and/or lactation.
* Denial of Informed Consent.
* Known allergy to ammonium chloride or to any of the ACF, or VDF excipients.
* Organ transplantation.
* Frailty score ≥ 5.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Department of Medicine, Sotiria General Hospital
UNKNOWN
Sponsor Role
collaborator
National and Kapodistrian University of Athens
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nikolaos Drakoulis, MD
Professor of Clinical Pharmacology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
En Ygeia Clinic
Athens, , Greece
Site Status
Sotiria General Hospital
Athens, , Greece
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Greece
References
Explore related publications, articles, or registry entries linked to this study.
Helenius A, Marsh M, White J. Inhibition of Semliki forest virus penetration by lysosomotropic weak bases. J Gen Virol. 1982 Jan;58 Pt 1:47-61. doi: 10.1099/0022-1317-58-1-47.
Reference Type
BACKGROUND
Zeichhardt H, Wetz K, Willingmann P, Habermehl KO. Entry of poliovirus type 1 and Mouse Elberfeld (ME) virus into HEp-2 cells: receptor-mediated endocytosis and endosomal or lysosomal uncoating. J Gen Virol. 1985 Mar;66 ( Pt 3):483-92. doi: 10.1099/0022-1317-66-3-483.
Reference Type
BACKGROUND
Yoshimura A, Ohnishi S. Uncoating of influenza virus in endosomes. J Virol. 1984 Aug;51(2):497-504. doi: 10.1128/JVI.51.2.497-504.1984.
Reference Type
BACKGROUND
Superti F, Seganti L, Orsi N, Divizia M, Gabrieli R, Pana A. The effect of lipophilic amines on the growth of hepatitis A virus in Frp/3 cells. Arch Virol. 1987;96(3-4):289-96. doi: 10.1007/BF01320970.
Reference Type
BACKGROUND
Silva PJS, Sagastizabal C, Nonato LG, Struchiner CJ, Pereira T. Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions. Proc Natl Acad Sci U S A. 2021 Aug 31;118(35):e2104640118. doi: 10.1073/pnas.2104640118.
Reference Type
BACKGROUND
Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol. 2022 Sep;32(5):e2381. doi: 10.1002/rmv.2381. Epub 2022 Jul 20.
Reference Type
BACKGROUND
Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, Campbell H, Demont C, Nyawanda BO, Chu HY, Stoszek SK, Krishnan A, Openshaw P, Falsey AR, Nair H; RESCEU Investigators. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583. doi: 10.1093/infdis/jiz059.
Reference Type
BACKGROUND
Shang C, Zhuang X, Zhang H, Li Y, Zhu Y, Lu J, Ge C, Cong J, Li T, Tian M, Jin N, Li X. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virol J. 2021 Feb 27;18(1):46. doi: 10.1186/s12985-021-01515-1.
Reference Type
BACKGROUND
Prabhakara C, Godbole R, Sil P, Jahnavi S, Gulzar SE, van Zanten TS, Sheth D, Subhash N, Chandra A, Shivaraj A, Panikulam P, U I, Nuthakki VK, Puthiyapurayil TP, Ahmed R, Najar AH, Lingamallu SM, Das S, Mahajan B, Vemula P, Bharate SB, Singh PP, Vishwakarma R, Guha A, Sundaramurthy V, Mayor S. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors. PLoS Pathog. 2021 Jul 12;17(7):e1009706. doi: 10.1371/journal.ppat.1009706. eCollection 2021 Jul.
Reference Type
BACKGROUND
Pifarre I Arolas H, Acosta E, Lopez-Casasnovas G, Lo A, Nicodemo C, Riffe T, Myrskyla M. Years of life lost to COVID-19 in 81 countries. Sci Rep. 2021 Feb 18;11(1):3504. doi: 10.1038/s41598-021-83040-3.
Reference Type
BACKGROUND
Nguyen NN, Houhamdi L, Hoang VT, Stoupan D, Fournier PE, Raoult D, Colson P, Gautret P. High rate of reinfection with the SARS-CoV-2 Omicron variant. J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.04.034. Epub 2022 Apr 23. No abstract available.
Reference Type
BACKGROUND
Mizzen L, Hilton A, Cheley S, Anderson R. Attenuation of murine coronavirus infection by ammonium chloride. Virology. 1985 Apr 30;142(2):378-88. doi: 10.1016/0042-6822(85)90345-9.
Reference Type
BACKGROUND
Maltezou HC, Raftopoulos V, Vorou R, Papadima K, Mellou K, Spanakis N, Kossyvakis A, Gioula G, Exindari M, Froukala E, Martinez-Gonzalez B, Panayiotakopoulos G, Papa A, Mentis A, Tsakris A. Association Between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients With SARS-CoV-2 Infection. J Infect Dis. 2021 Apr 8;223(7):1132-1138. doi: 10.1093/infdis/jiaa804.
Reference Type
BACKGROUND
Maltezou HC, Papanikolopoulou A, Vassiliu S, Theodoridou K, Nikolopoulou G, Sipsas NV. COVID-19 and Respiratory Virus Co-Infections: A Systematic Review of the Literature. Viruses. 2023 Mar 28;15(4):865. doi: 10.3390/v15040865.
Reference Type
BACKGROUND
Maltezou HC, Papadima K, Gkolfinopoulou K, Ferentinos G, Mouratidou E, Andreopoulou A, Pavli A, Magaziotou I, Georgakopoulou T, Mellou K, Vorou R, Antoniadou A, Stathakarou A, Chrysochoou A, Gogos C, Karaiskou A, Kotanidou A, Koutsoukou A, Marangos M, Mentis A, Metallidis S, Papa A, Pefanis A, Tsakris A, Sipsas NV. Coronavirus disease 2019 pandemic in Greece, February 26 - May 3, 2020: The first wave. Travel Med Infect Dis. 2021 May-Jun;41:102051. doi: 10.1016/j.tmaid.2021.102051. Epub 2021 Apr 2. No abstract available.
Reference Type
BACKGROUND
Maltezou HC, Krumbholz B, Mavrouli M, Tseroni M, Gamaletsou MN, Botsa E, Anastassopoulou C, Gikas A, Fournarakou E, Kavieri M, Koureli A, Mandilara D, Marinopoulou A, Theodorikakou A, Tsiahris P, Zarzali A, Pournaras S, Lourida A, Elefsiniotis I, Vrioni G, Sipsas NV, Tsakris A. A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021. J Med Virol. 2022 Apr;94(4):1465-1472. doi: 10.1002/jmv.27465. Epub 2021 Dec 4.
Reference Type
BACKGROUND
Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simoes EAF, Campbell H, Pariente AB, Bardach D, Bassat Q, Casalegno JS, Chakhunashvili G, Crawford N, Danilenko D, Do LAH, Echavarria M, Gentile A, Gordon A, Heikkinen T, Huang QS, Jullien S, Krishnan A, Lopez EL, Markic J, Mira-Iglesias A, Moore HC, Moyes J, Mwananyanda L, Nokes DJ, Noordeen F, Obodai E, Palani N, Romero C, Salimi V, Satav A, Seo E, Shchomak Z, Singleton R, Stolyarov K, Stoszek SK, von Gottberg A, Wurzel D, Yoshida LM, Yung CF, Zar HJ; Respiratory Virus Global Epidemiology Network; Nair H; RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
Reference Type
BACKGROUND
Grange Z, Buelo A, Sullivan C, Moore E, Agrawal U, Boukhari K, McLaughlan I, Stockton D, McCowan C, Robertson C, Sheikh A, Murray JLK. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. Lancet. 2021 Nov 13;398(10313):1799-1800. doi: 10.1016/S0140-6736(21)02316-3. Epub 2021 Oct 28. No abstract available.
Reference Type
BACKGROUND
Georgakopoulou VE, Vlachogiannis NI, Basoulis D, Eliadi I, Georgiopoulos G, Karamanakos G, Makrodimitri S, Samara S, Triantafyllou M, Voutsinas PM, Ntziora F, Psichogiou M, Samarkos M, Sfikakis PP, Sipsas NV. A Simple Prognostic Score for Critical COVID-19 Derived from Patients without Comorbidities Performs Well in Unselected Patients. J Clin Med. 2022 Mar 25;11(7):1810. doi: 10.3390/jcm11071810.
Reference Type
BACKGROUND
Fournier PE, Houhamdi L, Colson P, Cortaredona S, Delorme L, Cassagne C, Lagier JC, Chaudet H, Tissot-Dupont H, Giraud-Gatineau A, Fenollar F, Million M, Raoult D. SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhone District, Southern France, 2021. Front Microbiol. 2022 Jan 18;12:796807. doi: 10.3389/fmicb.2021.796807. eCollection 2021.
Reference Type
BACKGROUND
Faust JS, Chen AJ, Nguemeni Tiako MJ, Du C, Li SX, Krumholz HM, Barnett ML. Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020. JAMA Intern Med. 2022 Jan 1;182(1):87-90. doi: 10.1001/jamainternmed.2021.6734.
Reference Type
BACKGROUND
Qu P, Faraone J, Evans JP, Zou X, Zheng YM, Carlin C, Bednash JS, Lozanski G, Mallampalli RK, Saif LJ, Oltz EM, Mohler PJ, Gumina RJ, Liu SL. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. N Engl J Med. 2022 Jun 30;386(26):2526-2528. doi: 10.1056/NEJMc2206725. Epub 2022 Jun 15. No abstract available.
Reference Type
BACKGROUND
Siami Z, Aghajanian S, Mansouri S, Mokhames Z, Pakzad R, Kabir K, Norouzi M, Soleimani A, Hedayat Yaghoobi M, Shadabi S, Tajbakhsh R, Kargar Kheirabad A, Mozhgani SH. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial. Int J Infect Dis. 2021 Jul;108:306-308. doi: 10.1016/j.ijid.2021.04.043. Epub 2021 Apr 18.
Reference Type
BACKGROUND
Hidvegi M, Nichelatti M. Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe. Isr Med Assoc J. 2020 Aug;22(8):501-504.
Reference Type
BACKGROUND
Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, D'Ostilio D, Vignolo E, Donatelli I, Cassone A. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J. 2007 May 3;4:39. doi: 10.1186/1743-422X-4-39.
Reference Type
BACKGROUND
Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022 Jun 2;13(1):3082. doi: 10.1038/s41467-022-30895-3.
Reference Type
BACKGROUND
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, Alroy-Preis S, Ash N, Huppert A, Milo R. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022 May 5;386(18):1712-1720. doi: 10.1056/NEJMoa2201570. Epub 2022 Apr 5.
Reference Type
BACKGROUND
Cicero AFG, Fogacci F, Borghi C. Vitamin D Supplementation and COVID-19 Outcomes: Mounting Evidence and Fewer Doubts. Nutrients. 2022 Aug 31;14(17):3584. doi: 10.3390/nu14173584.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sotiria GH 14328/17-05-2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
NCT04539262
COMPLETED
PHASE1/PHASE2
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
NCT04523181
COMPLETED
PHASE2
Study of VIR-2482 in Healthy Volunteers
NCT04033406
COMPLETED
PHASE1
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
NCT05567952
COMPLETED
PHASE2
A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study
NCT02588521
COMPLETED
PHASE1
Effect of Hypertonic Saturated Saline Mouth Rinse on Covid-19 Virus in Vivo.
NCT04842721
WITHDRAWN
PHASE2
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
NCT02635724
COMPLETED
PHASE3
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
NCT04467151
WITHDRAWN
PHASE2
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
NCT05030324
COMPLETED
PHASE2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
NCT04373460
COMPLETED
PHASE2
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial
NCT04405310
COMPLETED
PHASE2
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
NCT03455491
COMPLETED
PHASE2
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
NCT04474340
UNKNOWN
PHASE1
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
NCT03459391
COMPLETED
PHASE1
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
NCT00705406
COMPLETED
PHASE2
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
NCT05047601
COMPLETED
PHASE2/PHASE3
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
NCT04679350
TERMINATED
PHASE2
ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04501978
COMPLETED
PHASE3
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus
NCT04344379
COMPLETED
PHASE3
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
NCT04676971
COMPLETED
PHASE2
Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia
NCT03900988
RECRUITING
PHASE3
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
NCT05438602
COMPLETED
PHASE2
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
NCT04939428
COMPLETED
PHASE3
Primary Prevention of Infection by COVID-19 in Workers
NCT04420260
COMPLETED
NA
A Trial of Remdesivir in Adults With Severe COVID-19
NCT04257656
TERMINATED
PHASE3